Physician profile
Merene V Thomas
NPI 1528559325
$1,865.94
in general payments reported to CMS, 2019-2025
24 companies · $536 in 2025
The $536 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $112 · 2023: $396 · 2024: $821 · 2025: $536.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,754.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,753.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $291.03 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Echosens North America, INC. | $288.27 | 2025 | Fibroscan |
| Abbvie INC. | $286.25 | 2022-2025 | Qulipta, Vraylar, Ubrelvy |
| Astellas Pharma US INC | $140.90 | 2022-2024 | Veozah |
| Pfizer INC. | $124.45 | 2024-2025 | |
| Lilly USA, LLC | $95.60 | 2023-2025 | Zepbound, Jardiance, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $89.28 | 2022-2025 | Airsupra, Farxiga |
| Shield Therapeutics INC | $68.91 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.32 | 2024-2025 | Jardiance |
| Corcept Therapeutics | $46.85 | 2024 | Korlym |
| Medtronic, INC. | $45.90 | 2023-2024 | Intellis Adaptivestim |
| Exact Sciences Corporation | $43.18 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $43.00 | 2022 | |
| Glaxosmithkline, LLC. | $41.77 | 2023 | Arexvy, Shingrix |
| Dexcom, INC. | $34.64 | 2023-2025 | Dexcom G6 Transmitter |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $32.89 | 2024 | Immunocap |
| Acella Pharmaceuticals, LLC | $22.29 | 2024 | NP Thyroid 60 |
| Optinose US, INC. | $21.22 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.34 | 2024 | Xifaxan |
| Currax Pharmaceuticals LLC | $14.90 | 2022 | |
| Antares Pharma, INC. | $14.73 | 2025 | Xyosted |
| Inspire Medical Systems, INC. | $14.41 | 2023 | Inspire |
| Bayer Healthcare Pharmaceuticals INC. | $13.52 | 2023 | |
| Lundbeck LLC | $13.29 | 2024 | Vyepti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Merene Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.